FDA Approves BioGaia's Request for Orphan Drug Designation
8/6/2013 9:22:53 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Necrotizing enterocolitis (NEC) is a rare and extremely severe disease that
affects premature infants. BioGaia is in a very early stage of investigating the
possibilities of developing a drug within this field and has submitted a request
for orphan drug designation in the USA. The FDA Office of Orphan Product
Development has now approved BioGaia’s request.
Help employers find you! Check out all the jobs and post your resume.
comments powered by